Nov 10, 2026 7:30 am EST Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Nov 9, 2026 6:35 am EST Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress
Nov 9, 2026 6:30 am EST Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement
Nov 2, 2026 7:46 am EST Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2026 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 18, 2026 7:30 am EDT Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
Sep 16, 2026 7:30 am EDT Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
Sep 2, 2026 7:30 am EDT Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Sep 1, 2026 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 13, 2026 7:30 am EDT Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
